Moderna Inc (MRNA)
125.00
-0.59
(-0.47%)
USD |
NASDAQ |
May 03, 16:00
125.43
+0.43
(+0.34%)
After-Hours: 20:00
Moderna SG&A Expense (Quarterly): 274.00M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 274.00M |
December 31, 2023 | 470.00M |
September 30, 2023 | 442.00M |
June 30, 2023 | 332.00M |
March 31, 2023 | 305.00M |
December 31, 2022 | 375.00M |
September 30, 2022 | 278.00M |
June 30, 2022 | 211.00M |
March 31, 2022 | 268.00M |
December 31, 2021 | 201.00M |
September 30, 2021 | 168.00M |
June 30, 2021 | 121.00M |
March 31, 2021 | 77.00M |
Date | Value |
---|---|
December 31, 2020 | 79.00M |
September 30, 2020 | 48.00M |
June 30, 2020 | 37.00M |
March 31, 2020 | 24.00M |
December 31, 2019 | 26.09M |
September 30, 2019 | 28.17M |
June 30, 2019 | 28.49M |
March 31, 2019 | 27.25M |
December 31, 2018 | 38.02M |
September 30, 2018 | 18.52M |
June 30, 2018 | 21.39M |
March 31, 2018 | 16.32M |
December 31, 2017 | 15.90M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
24.00M
Minimum
Mar 2020
470.00M
Maximum
Dec 2023
189.64M
Average
184.50M
Median
SG&A Expense (Quarterly) Benchmarks
Merck & Co Inc | 2.483B |
Pfizer Inc | 3.495B |
Eli Lilly and Co | 1.836B |
Johnson & Johnson | 5.057B |
Novavax Inc | 155.24M |